Phase I Study of ZL-1310 Pharmacokinetics and Tolerability in Patients with Small Cell Lung Cancer

The primary objective of this study is to evaluate the **tolerability** and pharmacokinetics of ZL-1310 in patients with **Small Cell Lung Cancer**. This involves determining a suitable dose of ZL-1310 by assessing how different doses are tolerated by the body, as well as understanding how the body absorbs, distributes, metabolizes, and excretes the drug. The clinical relevance of this study lies in optimizing the therapeutic regimen for patients with Small Cell Lung Cancer, potentially improving treatment outcomes and minimizing adverse effects.

The clinical trial involves a total of **89 participants** diagnosed with **Small Cell Lung Cancer**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected to ensure a diverse representation of the general population, including vulnerable groups. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information regarding the main objective or specific inclusion and exclusion criteria for this study.

The clinical trial is designed to evaluate the safety, tolerability, and pharmacokinetics of **ZL-1310** in patients diagnosed with **Small Cell Lung Cancer**. This study is a Phase 1 trial, which is typically the first stage in testing a new drug in humans. The trial employs a randomized, double-blind, and controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is November 22, 2024, with an anticipated completion date of October 1, 2026, indicating an overall trial duration of approximately two years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation, including medical history, physical examination, and laboratory tests. Following successful screening, participants will be randomly assigned to receive different doses of ZL-1310 or a control, with neither the participants nor the investigators aware of the group assignments, maintaining the double-blind nature of the study.

Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' health, assess drug tolerability, and collect pharmacokinetic data. These visits will include physical examinations, laboratory tests, and assessments of any adverse events. The end-of-study visit will mark the conclusion of the participant's involvement, where final evaluations will be conducted to gather comprehensive data on the drug's effects.

The expected length of participant involvement will vary depending on individual response and tolerance to the treatment, but it is anticipated to last throughout the trial's duration unless early termination is warranted. Conditions that may lead to early withdrawal from the study include significant adverse reactions, non-compliance with study procedures, or withdrawal of consent by the participant. The trial's design and procedures are structured to ensure the collection of robust data while prioritizing participant safety and adherence to ethical standards.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of these details precludes a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is November 22, 2024, with an anticipated end date of October 1, 2026. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 1 trials typically involve initial assessments of pharmacokinetics and pharmacodynamics, which may include measuring **biomarker** levels or other relevant physiological responses. The methods and schedule for measuring, collecting, and analyzing these parameters are not specified, but standard practices in Phase 1 trials often involve frequent monitoring and data collection at various timepoints throughout the treatment period. The trial's design and execution will adhere to regulatory standards to ensure the reliability and validity of the efficacy assessments.